Genetic Vaccines and Therapy

Table 1 Humoral immune responses to vaccination

From: Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensischallenge

Titre (and percentage of animals responding) of specific IgG1 and IgG2a antibodies in ELISA.
ELISA	Omp25-GST		IalB		16M
	IgG1	IgG2a	IgG1	IgG2a	IgG1	IgG2a
p-omp25 [X1]	Neg	1/320 (60%)	ND	ND	Neg	Neg
p-omp25 [X4]	1/640 (100%)	1/1280 (100%)	ND	ND	1/420 (100%)	1/520 (100%)
L-p-omp25	1/320 (70%)	1/1000 (100%)	ND	ND	1/640 (70%)	1/1280 (100%)
p-ialB [X1]	ND	ND	Neg	Neg	Neg	Neg
p-ialB [X4]	ND	ND	1/5210 (100%)	1/5210 (100%)	1/5120 (100%)	1/5120 (100%)
L-p-ialB	ND	ND	1/270 (80%)	1/40*(10%)	1/500 (80%)	1/120 (10%)
pcDNA3.1 [X1]	Neg	Neg	Neg	Neg	Neg	Neg
pcDNA3.1 [X4]	Neg	Neg	Neg	Neg	Neg	Neg
L-pcDNA3.1	Neg	Neg	Neg	Neg	Neg	Neg
Uncomplexed Liposome	Neg	Neg	Neg	Neg	Neg	Neg
Rev.1a	Neg	Neg	Neg	Neg	Neg	Neg
Rev.1b	1/640 (100%)	1/640 (100%)	Neg	Neg	1/2560 (100%)	1/2560 (100%)
PBS	Neg	Neg	Neg	Neg	Neg	Neg

Rev.1a, serum sample taken at two weeks post-vaccination. Rev.1b serum sample taken at 12 weeks post-vaccination. Neg: All individual OD values below assay C/O. ND: Sample not tested. The number of individual sera per group for each assay n ≥ 10.

Back to article page